At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Not specified by the sponsor
- How long the study runs
- Study runs about 120 months (dates as stated)
- About the drug or intervention
- Not specified by the sponsor
- Patient visit burden
- Not specified by the sponsor
In plain English
The Vitaccess Real MG Registry is a study for people with myasthenia gravis (MG). It is run by Vitaccess Ltd. What the study involves is not stated — ask the trial team.
Who can take part
- You are aged 18 or over.
- A doctor has confirmed that you have MG.
- You live in one of the countries the study covers.
- You have access to a smartphone, tablet, computer or laptop.
- You are willing and able to give your informed agreement (consent) to take part, in your own language.
Who may not be able to
- You are taking part in another clinical trial at the time you join this study.
What taking part involves
- • Not stated — ask the trial team
Time commitment: Not stated — ask the trial team
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 600
- Started
- 2024-07-31
- Last checked
- 2025-07
Plain English Summary
What is this study?
- • Testing a new treatment for myasthenia gravis
- • Clinical study - 600 participants
- • Vitaccess Real MG (VRMG) is a patient registry designed to capture longitudinal observational data on myasthenia gravis (MG), its treatment, and impact on symptoms, daily activities, and quality of life (QoL)
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with myasthenia gravis
Where?
- • London - Vitaccess Ltd
- • Birmingham - University Hospitals Birmingham
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
Vitaccess Real MG (VRMG) is a patient registry designed to capture longitudinal observational data on myasthenia gravis (MG), its treatment, and impact on symptoms, daily activities, and quality of life (QoL). The duration of the registry is 10 years from launch, and approximately 600 patients will be recruited in the US and Europe with no defined upper limit. The registry will link relevant patient- and healthcare professional (HCP)-reported data with clinical data from medical records. Patients will be recruited at clinical sites in all participating countries. In the US only, patients can additionally be recruited via community neurologists or direct-to-patient recruitment.
More detail
Traditional site recruitment (all countries): Adult patients who are being treated for MG at one of the participating clinics or centers in one of the participating countries (currently the US and UK) at the time of enrolment and who meet the inclusion and exclusion criteria will be identified and approached by their clinical team and invited to participate in the registry. Patient-reported data will be collected via the VRMG Registry platform, a digital data capture platform accessible via any web-enabled platform (e.g., phone, tablet, laptop, computer). Custom survey and patient-reported outcomes data will be collected at baseline and at regular intervals thereafter for a follow-up period of up to 10 years. The data collected will capture the impact of MG on daily living, fatigue, and health-related quality of life. Site research teams will complete and update an eCRF (every six months ± one months) for each patient, including data from the patient's EMR. eCRFs that are completed within one months prior to or following each six-month mark will be considered within the same assessment window for analytics purposes so that patients will not be required to visit the clinical site for the purposes of the registry outside of their regular clinical visits. Community neurologist recruitment (US only): Community neurologists who are treating MG patients who would be eligible for participation in the registry will be able to register their interest for involvement and provide details of their credentials via an informational website. Approved community neurologists will identify and approach potential participants, who will participate in the registry as normal. Clinical data will be captured from participants' electronic medical records via an EMR aggregator. Direct-to-patient recruitment (US only): A cohort of US-based participants in the MyRealWorld MG study - a longitudinal observational study in MG that Vitaccess has run since 2019 - have provided consent to be contacted by Vitaccess about future research. Vitaccess will contact this patient cohort directly via email to introduce them to the registry; patients can access the registry's informational website to get further information. Clinical data will be captured from participants' electronic medical records via an EMR aggregator. Patient-reported and eCRF data will be linked via a unique ID and PIN assigned to each participant at enrolment.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Adult (age ≥18 years) with a clinically-confirmed diagnosis of myasthenia gravis (MG).
- ✓Resident in one of the scope countries.
- ✓Access to a smartphone/tablet/computer/laptop
- ✓Willing and able to provide agreement to take part in their local language to take part in the study.
Who cannot take part
- ✗Participation in a clinical trial at the time of study enrolment.
See the full criteria
Where Is This Study? (2 UK sites)
Vitaccess Ltd
London W12 7RZ, United Kingdom
University Hospitals Birmingham
Birmingham B15 2GW, United Kingdom
How to Get in Touch
Mark JW Larkin, PhD
Sponsor contactCONTACT
